Egetis Therapeutics Valuation
Is EGTXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EGTXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EGTXS (SEK6.95) is trading below our estimate of fair value (SEK104.41)
Significantly Below Fair Value: EGTXS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EGTXS?
Key metric: As EGTXS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EGTXS's PS Ratio? | |
|---|---|
| PS Ratio | 19x |
| Sales | SEK 70.80m |
| Market Cap | SEK 1.34b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 17.8x |
| Enterprise Value/EBITDA | -4.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EGTXS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.4x | ||
BVXP Bioventix | 14.4x | n/a | UK£195.7m |
TRX Tissue Regenix Group | 1.6x | 15.1% | UK£40.6m |
AVCT Avacta Group | 7.8x | 0.4% | UK£182.9m |
AREC Arecor Therapeutics | 5.9x | 35.2% | UK£28.9m |
EGTXS Egetis Therapeutics | 19x | 70.3% | SEK 1.3b |
Price-To-Sales vs Peers: EGTXS is expensive based on its Price-To-Sales Ratio (19x) compared to the peer average (7.9x).
Price to Sales Ratio vs Industry
How does EGTXS's PS Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: EGTXS is expensive based on its Price-To-Sales Ratio (19x) compared to the European Biotechs industry average (9.1x).
Price to Sales Ratio vs Fair Ratio
What is EGTXS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 19x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate EGTXS's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Formycon
€848.4m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.50
7D
4.3%
1Y
-21.3%
Regeneron Pharmaceuticals
US$80.6b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$749.75
7D
0.4%
1Y
-5.8%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€63.05
7D
2.4%
1Y
12.5%